G6PD and colorectal carcinoma: Moreover, epicatechin gallate (EGCG), a putative G6PD inhibitor, has also been investigated in CRC, and has been shown to reduce the de novo synthesis of fatty acids and the pentose phosphate pathway in HT29 cells (Sánchez-Tena et al., 2013).